At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 185 enrolled
Drug / intervention
RhACE2 APN01 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
In Brief
A Phase 2 clinical trial evaluating RhACE2 APN01 and Physiological saline solution for COVID-19. Completed, enrolled 185 participants across 22 sites in 5 countries.
Detailed Summary
Recombinant human angotensin-converting enzyme 2 (rhACE2) as a treatment for patients with COVID-19 to block viral entry and decrease viral replication.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesAustria, Denmark, Germany, Russia, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartApr 2020
Primary CompletionDec 2020
TodayJul 2026
First PostedApr 6, 2020
Enrollment StartApr 30, 2020
Primary CompletionDec 26, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.2 years ago
Interventions
RhACE2 APN01drug
Patients will be treated with APN01 intravenously twice daily (BID).
Physiological saline solutiondrug
Patients will be treated with placebo intravenously twice daily (BID).